In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback